Clinical Trial Update: Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update describes using erythromycin to promote readthrough of APC gene stop codons in Familial Adenomatous Polyposis (FAP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• ERYTHROMYCIN (ERYTHROMYCIN)

Snippet

Sponsor: michal roll | Conditions: FAP-Familial Adenomatous Polyposis | Phase 4 | Status: UNKNOWN